Mealey's (April 5, 2018, 2:04 PM EDT) -- BOSTON — Shareholders have not shown that pharmaceutical company Sarepta Therapeutics Inc. and three of its senior executives materially misrepresented investors that a 2014 new drug application (NDA) with the U.S. Food and Drug Administration for its Duchenne muscular dystrophy (DMD) treatment drug was likely even though the FDA had expressed concerns over the sufficiency of the company’s clinical data in making their federal securities law claims, a First Circuit U.S. Court of Appeals panel ruled April 4 in affirming a federal district court’s dismissal of the suit (William Kader, et al. v. Sarepta Therapeutics Inc., et al., No. 17-1139, 1st Cir., 2018 U.S. App. LEXIS 8563)....